Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 CHICAGO, February 26, 2026 BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev ® (levoketoconazole) in the United States District Court for the District of New Jersey against Torrent Pharmaceuticals Limited (along with its affiliate) and Somerset Therapeutics, LLC (along with its affiliates), each of which filed an Abbreviated New Drug Application ("ANDA") with the U.S. Food and Drug Administration (the "FDA") seeking approval to manufacture, use or sell a generic version of Recorlev ® (levoketoconazole) (each, an "ANDA Filer"). Xeris's
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]Seeking Alpha
- Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
XERS
Earnings
- 3/2/26 - Beat
XERS
Sec Filings
- 3/2/26 - Form 144
- 3/2/26 - Form S-8
- 3/2/26 - Form 10-K
- XERS's page on the SEC website